Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Vitamin C's hidden role in kidney stones revealed

NCT ID NCT04603898

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing This study
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study looks at how vitamin C (ascorbic acid) turns into oxalate, a key component of kidney stones. Researchers will give a special labeled vitamin C to 136 adults—both with and without kidney stones—and measure how much oxalate ends up in their urine. The goal is to understand if vitamin C contributes to stone formation, especially in people who are obese.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

90 people

The number who actually took part.

Started

Nov 2021

Expected to finish

Feb 2027

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

19 years and older

Sex

Anyone

Healthy volunteers

Accepted

You do not need to have the condition being studied to take part.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Able to provide informed consent * For stone formers: composition of most recent stone \> 50% calcium oxalate, no uric acid component * For stone formers: first time or recurrent calcium oxalate stone former with stone event within the prior 3 years * Two 24-hour urine collections with urinary 24-hour creatinine excretion within 20% of appropriate ratio of creatinine (mg) / body weigh (kg) for gender * Willingness to stop supplements (vitamins, Calcium (citrate or carbonate) and other minerals, herbal supplements, nutritional aids, probiotics) for 2 weeks before start and during study * Willingness to not undertake vigorous exercise during the study * Normal fasting blood Comprehensive Metabolic Panel (CMP) * Willingness to ingest menus prepared in Clinical Research Unit at University of Alabama at Birmingham * No food allergies or intolerance to any of the foods in study menus * If on medications for stone prevention (e.g. thiazides, citrate supplementation excluding calcium citrate), they should have been on a stable dose regimen for at least 8 weeks prior to and during screening, with no changes in dosing anticipated during study protocol. If on allopurinol for stone prevention, stop it for 2 weeks prior to screening and this will not be administered during the study as it has anti-oxidant properties. Exclusion Criteria: * Diabetes * Gout * Hypertension * Estimated Glomerular Filtration Rate (eGFR) less than 60ml/min/1.73m2 * Primary hyperoxaluria * Nephrotic syndrome * Enteric hyperoxaluria * Renal tubular acidosis * Primary hyperparathyroidism * Liver disease * Auto-immune disorder * Neurogenic bladder * Urinary diversion * Bariatric surgery * Active malignancy or treatment for malignancy within 12 months prior to screening * Pregnancy * Breastfeeding/nursing individuals * Females of child bearing age who are not able to use an effective method of birth control during the study * Mental/medical condition that is likely to impede successful study completion * Illness including flu/common cold/fever 14 days before study and during study * Diarrhea or other abnormal gastrointestinal event (e.g. abnormal bowel movements) 14 days before study or during study * Abnormal fasting CMP

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Kidney stone are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

Kidney Calculi nephrolithiasis

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Contacts and locations

Locations

  • University of Alabama at Birmingham

    Birmingham, Alabama, 35243-3353, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.